Adherence to inhaled therapy in COPD: Effects on survival and exacerbations

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 2, 2010, Pages 115-117

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Adherence; Chronic obstructive pulmonary disease; Inhaled therapy; Morbidity; Mortality

Indexed keywords

FLUTICASONE; PLACEBO; SALMETEROL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; HOSPITAL ADMISSION; HUMAN; MORBIDITY; MORTALITY; NOTE; PATIENT COMPLIANCE; PROGNOSIS; QUALITY OF LIFE; RISK REDUCTION; SURVIVAL RATE;

EID: 77950968171     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.10     Document Type: Note

References (4)

1. Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361(9356), 449-456 (2003). (Pubitemid 36173708)
2. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356(8), 775-789 (2007). (Pubitemid 46294610)
3. Vestbo J, Anderson JA, Calverley PM et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 64(11), 939-943 (2009).
4. Rand CS, Cowles MK, Wise RA, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am. J. Respir. Crit. Care Med. 2(152), 580-588 (1995).